AzTrials
AzTrials

Advanced Breast CancerPhase 2DEBBRAHNCT04420598

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

A Phase 2 study testing Trastuzumab deruxtecan in people with Advanced Breast Cancer and HER2-positive Breast Cancer, run by MedSIR at 16 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Trastuzumab deruxtecan
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
41 participants
Where
16 sitesin 2 countries
Study dates
25 May 2020to 4 Apr 2023
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed Informed Consent Form (ICF) prior to participation in any study-related activities.
  • Male or female patients ≥ 18 years at the time of signing ICF.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 for Cohorts 1 to 4 and 0-2 for cohort 5.
  • Life expectancy ≥ 12 weeks.
  • Histologically confirmed invasive breast cancer based on local testing on the most recent analyzed biopsy of the following breast cancer (BC) subtypes per 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria:
  • Cohort 1 and 3: HER2 positive status
Show all 49Show fewer
  • Cohort 4: HER2-low expressing status
  • Cohort 2 and 5: both HER2 positive and HER2-low expressing status
  • Note 1: According to the 2018 ASCO-CAP guidelines, HER2- positive status is defined as HER2 immunohistochemistry (IHC) 3+, in situ hybridization (ISH) ≥ 2.0, or average HER2 copy number ≥ 6.0 signals. HER2-low expressing status defined as IHC 2+ / ISH-negative or IHC 1+ (ISH-negative or untested).
  • Note 2: Central confirmation of HER2 is not required for study entry. However, tissue blocks, or slides, must be submitted to confirm BC subtype by a Sponsor-designated central laboratory retrospectively.
  • Unresectable locally advanced or metastatic disease documented by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent.
  • At least one brain lesion needed to be measurable (≥10 mm on T1-weighted, gadolinium-enhanced MRI) (study cohorts 2 to 4) or leptomeningeal carcinomatosis (LMC) with positive cerebrospinal fluid (CSF) cytology (study cohort 5).
  • Study cohort 1: History of BM that are non-progressing after WBRT and/or SRS and or surgery.
  • Study cohort 2: Presence of asymptomatic BM without clinical requirement for local intervention (WBRT and/or SRS and/or surgery).
  • Study cohorts 3 and 4: Evidence of new and/or progressive BM following previous WBRT and/or SRS and/or surgery.
  • Study cohort 5: Evidence of LMC with positive CSF cytology.
  • Previous treatments:
  • For HER2-positive patients have been previously treated with a taxane and at least one HER2-targeted therapy in the advanced scenario.
  • For HER2-low-expressing patients that also are endocrine receptor negative must have been previously treated with at least one chemotherapy regimen. If endocrine receptor positive, patients must have been previously treated with at least one chemotherapy and one endocrine regimen in the metastatic setting.
  • Patients must agree to collection of blood samples at the time of inclusion, at cycle 2 of treatment, and upon progression or study termination.
  • Note: In study cohort 5: Patients must agree to perform spinal taps or must be willing to have an Ommaya reservoir placed for CSF assessment, at baseline, every three weeks for 12 weeks (corresponding to the first 5 cycles of treatment) and every six weeks thereafter.
  • Willingness and ability to provide tumor biopsy (if feasible) from metastatic lesions or breast primary tumor both at the time of the inclusion and after disease progression in order to perform exploratory studies.
  • Note: If feasible, patients should provide a tissue sample at baseline from metastases amenable to biopsy (at sites of locoregional recurrence [skin, chest wall, breast or lymph nodes], or distant recurrence [bone, liver, lung or abdomen]) or as alternative from breast primary tumor, that will be obtained between progression to the prior regimen and inclusion in the study. Patients for whom tissue sample cannot be obtained (e.g., non-measurable disease, inaccessible tumor or subject safety concern) may submit an archived metastatic tumor specimen only upon agreement from the Sponsor. If feasible, an additional tissue sample should be collected at the end of treatment visit for patients who discontinue treatment due to disease progression.
  • Patients should have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before enrolment.
  • Adequate hematologic and organ function within 14 days before the first study treatment on Day 1 of Cycle 1, defined by the following:
  • Hematological: White blood cell (WBC) count 3 3.0 x 109/L, absolute neutrophil count (ANC) 3 1.5 x 109/L, platelet count 3 100.0 x109/L, and hemoglobin 3 9.0 g/dL. (Platelet, red blood cell transfusion as well as G-CSF administration are not allowed within 1 week of screening assessments).
  • Hepatic: Bilirubin ≤ 1.5 times the upper limit of normal (× ULN) (< 3 x ULN in the case of documented Gilbert's disease and/or liver metastases); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN (in the case of liver metastases ≤ 5 × ULN); alkaline phosphatase (ALP) ≤ 2 × ULN (≤ 5 × ULN in the case of liver and/or bone metastases ≤ 5 × ULN), serum albumin 3 2.5 g/dL
  • Renal: Serum creatinine £ 1.5 × ULN or creatinine clearance ≥ 30 mL/min based on Cockcroft-Gault equation (*Cockcroft-Gault equation: ([{140 - age in years} × {ACTUAL WEIGHT in kg}] divided by [{72 × serum creatinine in mg/dL} multiplied by 0.85 if female])) Coagulation: International Normalized Ratio (INR)/Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN (except for patients receiving anticoagulation therapy).
  • Note: Patients receiving heparin treatment should have an aPTT) between 1.5 and 2.5 × ULN (or patient value before starting heparin treatment). Patients receiving coumarin derivatives should have an INR between 2.0 and 3.0 assessed in two consecutive measurements one to four days apart. Patients should be on a stable anticoagulant regimen.
  • Has adequate treatment washout period before enrollment, as indicated:
  • Major surgery: > 4 weeks;
  • Radiation therapy: > 4 weeks (palliative stereotactic radiation therapy to other areas ≥ 2 weeks);
  • Anticancer systemic treatment (including immunotherapy, retinoid therapy, hormonal therapy): ≥ 3 weeks (≥ 2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel; ≥ 6 weeks for nitrosureas or mitomycin C);
  • Antibody based anti-cancer therapy:≥ 4 weeks;
  • Chloroquine/Hydroxychloroquine>14 days
  • Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤1 as determined by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5.0 (except for alopecia or other toxicities). Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee (e.g., Grade 2 chemotherapy-induced neuropathy).
  • Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Methods considered as highly effective methods of contraception include:
  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
  • Oral ii. Intravaginal iii. Transdermal
  • Progestogen-only hormonal contraception associated with inhibition of ovulation: iv. Oral v. Injectable vi. Implantable
  • Intrauterine device (IUD)
  • Intrauterine hormone-releasing system (IUS)
  • Bilateral tubal occlusion
  • Vasectomized partner
  • Complete sexual abstinence defined as refraining from heterosexual intercourse during and upon completion of the study and for at least 7 months after the last dose of study drug. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception.
  • Note: Non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol < 40 pg/mL [< 147 pmol/L] is confirmatory).
  • Male subjects must agree to not freeze or donate sperm starting at Screening and throughout the study period, and at least 7months after the final study drug administration. Preservation of sperm should be considered prior to enrolment in this study.
  • Female subjects must agree to not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.
  • Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, post-treatment follow-up and other study procedures.

Who cannot join

  • Patients will be excluded from the study if they meet ANY of the following criteria:
  • Inability to comply with study and follow-up procedures.
  • Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor.
  • Medical history of myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV), troponin levels consistent with myocardial infarction within 28 days prior to enrollment.
  • Corrected QT interval (QTc) prolongation to > 470 ms (females) or >450 ms (males) based on average of the screening triplicate12- lead ECG.
  • History of (non-infectious) interstitial lung disease (ILD) that required steroids, has current ILD, or where suspected ILD cannot be ruled out by imaging at screening.
Show all 25Show fewer
  • Clinically significant corneal disease in the opinion of the Investigator.
  • Spinal cord compression.
  • Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.
  • History of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
  • History of severe hypersensitivity reactions to other monoclonal antibodies.
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  • Patients with substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
  • Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Subjects should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)/ethics committee (EC).
  • Female patients who are pregnant or breastfeeding or planning to become pregnant.
  • No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy
  • Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 4 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study.
  • Radiotherapy within 4 weeks or limited-field palliative radiotherapy within 2 weeks prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade ≤ 1 and/or from whom ≥ 25% of the bone marrow has been previously irradiated.
  • Use of concurrent investigational agents or other concomitant anticancer therapies.
  • Use of intrathecal therapy for LMC
  • Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention).
  • Serious concomitant systemic disorder (e.g., active infection including HIV, active hepatitis, liver cirrhosis, end stage chronic renal disease) incompatible with the study (at the discretion of investigator).
  • Any of the following within 6 months of enrollment: severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade 32, coronary/peripheral artery bypass graft, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
  • Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade ≥ 2.
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (i.e. Rheumatoid arthritis, Sjogren's, sarcoidosis etc.), or prior pneumonectomy.

Trial locations and contacts

16 sites in 2 countries.

16 sites in 2 countries

Spain14 sites

  • Institut Català d'Oncologica ICO Badalona

    Badalona

  • Hospital Universitari Dexeus

    Barcelona, 08028

  • Hospital del Mar

    Barcelona

  • Institut Oncologic Baselga-Hospital Quiron Salud Barcelona

    Barcelona

  • Hospital Universitario Reina Sofia

    Córdoba

  • Institut Catala d'Oncologia ICO Hospitalet

    L'Hospitalet de Llobregat

  • Hospital Clínico San Carlos

    Madrid

  • Hospital Universitario 12 de Octubre

    Madrid

  • Hospital Universitario Ramon y Cajal

    Madrid

  • IOB- Complejo Hospitalario Ruber Juan Bravo

    Madrid

  • Hospital Universitario Virgen del Rocio

    Seville

  • Fundación Instituto Valenciano de Oncología (IVO)

    Valencia, 46009

  • Hospital Clinico Universitario de Valencia

    Valencia

  • Hospital Universitario Migue Servet

    Zaragoza

Other trials in Spain

Portugal2 sites

  • Champalimaud Center for the Unknown

    Lisbon

  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto)

    Porto

Other trials in Portugal

About this study

Official title: Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan(DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis

This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial

Read the detailed description

Pretreated, unresectable locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive or HER2-low expressing breast cancer (BC) with untreated or treated brain metastases (BMs) or leptomeningeal carcinomatosis (LMC).

Being tested
Trastuzumab deruxtecan
Keywords
Breast cancer, HER2, Brain metastases, Metastatic, unresectable, pretreated
Medical subject headings
Brain Neoplasms, Meningeal Carcinomatosis, Breast Neoplasms, Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Trastuzumab deruxtecanDrug

    Also called (DS-8201a)

    After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.

    In patients with hormone receptor (HR)-positive status (estrogen receptor [ER] and/or progesterone receptor [PgR]) administration of endocrine therapy is not allowed.

    In patients allocated in study cohort 5, administration of intrathecal therapy is not allowed

Study groups in NCT04420598
Study groupRoleWhat they receive
Trastuzumab deruxtecan (DS-8201a)Experimental* Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.); * Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM; * Cohort 3: HER2-positive BC with progressing BMs after local treatment; * Cohort 4: HER2-low expressing BC with progressing BMs after local treatment; * Cohort 5: HER2-positive or HER2-low expressing BC with LMC.
Receives: Drug: Trastuzumab deruxtecan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1)

    This outcome measure evaluates progression-free survival (PFS) in Cohort 1 over a 16-week period, using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.

    Measured: From baseline up to 16 weeks

  2. Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4)

    The proportion of patients achieving either Complete Response (CR) or Partial Response (PR) at any assessment time point, based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria

    Measured: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

  3. Overall Survival in Cohort 5

    Median of OS rate for patients

    Measured: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

Secondary outcomes (4)

  1. Intra-cranial Evaluation According to RANO-BM

    Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

    Measured: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

  2. Extra-cranial Evaluation According to RECIST v1.1

    This outcome measure assesses the extra-cranial response of metastatic lesions outside the brain using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.

    Measured: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

  3. Global Evaluation According to RECIST v1.1

    The global evaluation of tumor response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. This includes classification into categories such as Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD), based on changes in tumor size and the appearance of new lesions.

    Measured: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

  4. Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1

    The Clinical Benefit Rate (CBR) is a measure of the proportion of patients who achieve a clinically meaningful benefit from the treatment

    Measured: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2020
  2. Study start25 May 2020
  3. Primary completion30 Sep 2021
  4. Study completion4 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial. After confirmed eligibility, patients will be assigned to one of the following five study cohorts: * Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.); * Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM; * Cohort 3: HER2-positive BC with progressing BMs after local treatment; * Cohort 4: HER2-low expressing BC with progressing BMs after local treatment; * Cohort 5: HER2-positive or HER2-low expressing BC with LMC
Masking
None (open label)
Enrolment
41 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04420598
Sponsor's protocol ID
MEDOPP243
Other IDs
2019-001739-29, 2019
Acronym
DEBBRAH
Status last verified
Jun 2025
First submitted
25 May 2020
Last updated
24 Jun 2025
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Vaz Batista M, Perez-Garcia JM, Garrigos L, Garcia-Saenz JA, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernandez-Ortega A, Fernandez-Abad M, Iranzo V, Gion M, Martrat G, Alcala-Lopez D, Perez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortes J. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 2025 Jan 10;6(1):100502. doi: 10.1016/j.medj.2024.08.001. Epub 2024 Sep 11.

    PubMed 39265579

  • Vaz Batista M, Perez-Garcia JM, Cortez P, Garrigos L, Fernandez-Abad M, Gion M, Martinez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodriguez J, Martrat G, Perez-Escuredo J, Alcala-Lopez D, Sampayo-Cordero M, Braga S, Cortes J, Llombart-Cussac A. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 2024 Sep;9(9):103699. doi: 10.1016/j.esmoop.2024.103699. Epub 2024 Sep 9.

    PubMed 39255534

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Trastuzumab deruxtecan in people with Advanced Breast Cancer and HER2-positive Breast Cancer, run by MedSIR at 16 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 49 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Spain, Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 Jun 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) (time frame: From baseline up to 16 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04420598, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in